$REGN (Regeneron Pharmaceuticals, Inc.)

$REGN {{ '2015-11-04T14:38:37+0000' | timeago}} • Webcast

During 3Q15, $REGN submitted a Biologic License Application (BLA) to the FDA for Sarilumab targeting IL-6R for rheumatoid arthritis and is also actively preparing for a potential U.S. launch in 2016.

$REGN {{ '2017-11-08T20:41:09+0000' | timeago}} • Webcast

$REGN said Sanofi reimbursement of its commercialization-related expenses, was $90MM for 3Q17. "We are tightening and lowering our FY17 guidance of Sanofi reimbursement of Regeneron commercialization-related expenses to $350-375MM from our previous guidance range of $370-400MM," the company said.

$REGN {{ '2017-11-08T15:12:08+0000' | timeago}} • Infographic

$REGN Regeneron Pharmaceuticals, Inc. Earnings AlphaGraphic: Q3 2017 Highlights

$REGN {{ '2017-11-08T12:35:23+0000' | timeago}} • Announcement

$REGN sees EYLEA US net sales growth of approx 10% in FY17. Meanwhile, guidance for Sanofi reimbursement has been reduced to $350-375MM, from the earlier projection of $370-400MM.

$REGN {{ '2017-11-08T12:29:30+0000' | timeago}} • Announcement

$REGN's net product sales were $957MM in 3Q17, compared to $857MM in 3Q16. EYLEA net product sales in the US were $953MM during the quarter, compared to $854MM in the year-over period.

$REGN {{ '2017-11-08T12:19:24+0000' | timeago}} • Announcement

$REGN reported double-digit growth in top and bottom-line growth in 3Q17, driven by solid sales of EYLEA injection and Praluent. Revenues improved 23% from last year to $1.5Bil, while net income rose 46% to $388MM, or $3.32 per share. On an adjusted basis, net income grew 27% to $3.99 per share.

$REGN {{ '2017-10-16T14:56:28+0000' | timeago}} • Announcement

$REGN and $SNY announced positive results from a Phase 2 study of dupilumab in adults with active moderateto-severe eosinophilic esophagitis (a condition that causes swallowing difficulty). The study showed that patients who received dupilumab weekly reported a significant improvement in the ability to swallow versus placebo.

$REGN {{ '2017-10-16T13:04:52+0000' | timeago}} • Announcement

$REGN and Sanofi announced positive results from a Phase 2 investigational study of dupilumab in adults with active moderate-to-severe eosinophilic esophagitis. Eosinophilic esophagitis is a chronic, allergic inflammatory disease that damages the esophagus and prevents it from working properly, leading to difficulties swallowing and food impaction.

$REGN {{ '2017-10-05T17:28:07+0000' | timeago}} • Announcement

Sanofi and $REGN said the U.S. Court of Appeals for the Federal Circuit has ordered new trial and vacated permanent injunction in the dispute concerning $AMGN's asserted patent claims for antibodies targeting PCSK9. This ruling means that Sanofi and $REGN will continue marketing, selling and manufacturing Praluent (alirocumab) injection in the U.S.

$REGN {{ '2017-10-02T12:04:30+0000' | timeago}} • Announcement

Pharma company $REGN has entered into collaborations with the Biomedical Advanced Research & Development Authority to develop  treatments for infectious diseases. The first collaboration is focused on development of antibodies targeting up to 10 pathogens, while the second builds on a prior agreement to develop a potential therapy for Ebola virus.

$REGN {{ '2017-09-28T12:24:36+0000' | timeago}} • Announcement

$REGN and $SNY have announced that the European Commission has granted marketing authorization for DUPIXENT (dupilumab), for use in adults with moderate-to-severe atopic dermatitis (AD) who are candidates for systemic therapy. AD, a form of eczema, is a chronic inflammatory disease with symptoms often appearing as a rash on the skin.

$REGN {{ '2017-09-18T10:59:56+0000' | timeago}} • Announcement

Pharma company $REGN and healthcare firm $SNY said a study showed that Dupixent, which is indicated for the treatment of atopic dermatitis, significantly improved overall disease severity. It also met the primary end point - the proportion of patients that achieved a 75% or greater improvement at 16 weeks from baseline.

$REGN {{ '2017-09-11T11:11:52+0000' | timeago}} • Announcement

$REGN and Sanofi announced positive dupilumab topline results from phase 3 trial in uncontrolled persistent asthma. The investigational dupilumab lowered severe asthma attacks and improved lung function. The companies plan to submit a Supplemental Biologics License Application (sBLA) to the U.S. FDA by the end of this year.

$REGN {{ '2017-08-14T13:55:04+0000' | timeago}} • Announcement

$REGN has announced that it would discontinue developing its drug to prevent respiratory syncytial virus (RSV) infections in infants. Its Phase 3 study evaluating suptavumab, an antibody to RSV, did not meet its primary endpoint of preventing the infection following which the company planned to stop further clinical development of this antibody.

$REGN {{ '2017-08-03T14:59:22+0000' | timeago}} • Webcast

The US sales of $REGN’s flagship macular degeneration drug EYLEA rose 10% YoY in the first half of 2017, driven by higher demand and increased market share. Regeneron expects to fully utilize the $130MM annual funding from its collaborator Sanofi, under an antibody discovery agreement, by the end of the third quarter.

$REGN {{ '2017-08-03T14:30:54+0000' | timeago}} • Webcast

$REGN said its arthritis drug Kevzara received approval from the US FDA and the European Commission in 2Q17. In the second half of this year, topline data from phase-2 studies on wet age related macular degeneration and diabetic macular edema are expected to be published. Results from study on a cardiovascular drug will be released in early 2018.

$REGN {{ '2017-08-03T12:12:28+0000' | timeago}} • Announcement

$REGN raised sales growth forecast for FY17 to 10% from the earlier outlook of single-digit increase. The company anticipates non-GAAP R&D expenses between $925MM and $965MM. The guidance of non-GAAP selling, general and administrative expenses has been raised to the range of $1.12-$1.16Bil. Regeneron sees effective tax rate of 27-31% for the year.

$REGN {{ '2017-08-03T11:54:57+0000' | timeago}} • Announcement

Earnings of pharmaceuticals company $REGN nearly doubled to $388MM in 2Q17 as strong sales of its leading products, including the EYLEA injection, lifted revenues by 21% to $1.47Bil. EPS grew 48%YoY to $3.34, while non-GAAP earnings advanced to $4.17 per share. The higher revenues resulted in an 88% gain in operating income.

$REGN {{ '2017-07-21T15:50:38+0000' | timeago}} • Announcement

$REGN and $SNY announced that the European Medicine Agency's Committee for Medicinal Products for Human Use has given a positive opinion for the marketing authorization of Dupixent (dupilumab), recommending its approval in Europe for use in adults with moderate-to-severe atopic dermatitis who are candidates for systemic therapy.

$REGN {{ '2017-06-22T14:02:42+0000' | timeago}} • Announcement

$REGN provided details of the royalty it receives on any sales of canakinumab (ACZ885). $REGN received a royalty on worldwide net sales of canakinumab; the royalty rate starts at 4% and reaches 15% when canakinumab annual sales exceed $1.5Bil.

$REGN {{ '2017-06-12T10:58:03+0000' | timeago}} • Announcement

$REGN and $SNY announced positive results from two Phase 3b/4 ODYSSEY-DM trials in patients with diabetes. In the studies, Praluent, when administered on top of maximally tolerated doses of statins, significantly reduced low-density lipoprotein cholesterol, the primary endpoint of the study.

Recent Transcripts

CORI (Corium International, Inc.)
Thursday, November 16 2017 - 10:00pm
TEAR (TearLab Corporation)
Monday, November 13 2017 - 9:30pm
SGYP (Synergy Pharmaceuticals, Inc.)
Thursday, November 9 2017 - 9:30pm
ENDP (Endo International plc)
Thursday, November 9 2017 - 9:30pm
ENSG (The Ensign Group, Inc.)
Thursday, November 9 2017 - 6:00pm
REGN (Regeneron Pharmaceuticals, Inc.)
Wednesday, November 8 2017 - 1:30pm
TSRO (Tesaro, Inc.)
Tuesday, November 7 2017 - 9:15pm
SUPN (Supernus Pharmaceuticals, Inc.)
Tuesday, November 7 2017 - 2:00pm
IMGN (ImmunoGen, Inc.)
Friday, November 3 2017 - 12:00pm
CORT (Corcept Therapeutics Incorporated)
Thursday, November 2 2017 - 9:00pm
IRIX (IRIDEX Corporation)
Thursday, November 2 2017 - 9:00pm
TECH (Bio-Techne Corp.)
Tuesday, October 31 2017 - 1:00pm
TNDM (Tandem Diabetes Care, Inc.)
Thursday, October 26 2017 - 8:30pm
SGEN (Seattle Genetics, Inc.)
Thursday, October 26 2017 - 8:30pm
GILD (Gilead Sciences Inc.)
Thursday, October 26 2017 - 8:30pm
BMY (Bristol-Myers Squibb Company)
Thursday, October 26 2017 - 2:30pm
AMGN (Amgen Inc)
Wednesday, October 25 2017 - 9:00pm
UTHR (United Therapeutics Corporation)
Wednesday, October 25 2017 - 1:00pm
MDCO (The Medicines Company)
Wednesday, October 25 2017 - 12:30pm
BIIB (Biogen Inc.)
Tuesday, October 24 2017 - 12:30pm

AlphaGraphics you may like